06:11 AM EDT, 03/15/2021 (MT Newswires) -- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH and TSX: AUP) was at last look up about 3% in US pre-market after announcing a "favorable" assessment regarding the cost-effectiveness and value of LUPKYNIS (voclosporin), based on an independent analysis issued by the Institute for Clinical and Economic Review (ICER) in a revised Evidence Report issued on March 12, 2021.

According to a statement, the report finds that LUPKYNIS represents an "important new treatment option for patients living with lupus nephritis (LN) and at the estimated net price, determined the therapy to be priced in alignment with ICER's recommended health-benefit price benchmark ranges."

Price: 17.14, Change: +0.05, Percent Change: +0.29